FDA

The FDA has approved the CustomVue monovision lasik device from AMO/Visx Inc. of Santa Clara, Calif. The product is designed to fully correct nearsightedness in the patient’s dominant eye but only partially correct it in the nondominant one, allowing patients to view both nearby and distant objects after an adjustment period. In contrast to traditional lasik, the procedure may reduce the need for patients over the age of 40 to wear reading glasses.





LATEST NEWS

• The Winds of Change Are Blowing Through the Photonics Industry
  May 3, 2024
• PsiQuantum to Build Utility-Scale Quantum Computer in Australia
  May 3, 2024
• Tyndall, MIT Partner on Sustainable Chip Production Processes: Week in Brief: 5/3/24
  May 3, 2024
• Headwall Taps Jim Gareau to Lead Optical Components and Assemblies Unit
  May 2, 2024
• Cognex Names Former Siemens VP Dennis Fehr CFO
  May 2, 2024
• 3D Holography Integrated Glasses Could Unlock Mixed Reality
  May 2, 2024
• Generative AI Achieves Superresolution with Minimal Tuning
  May 2, 2024
• AmeriCOM Adds President and CEO: People in the News: 5/1/24
  May 1, 2024